BioSpero
Revolutionizing drug development with human-like organ models for safer, ethical testing.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | KRW1.2b | Late VC | |
| Total Funding | 000k | ||
Related Content
BioSpero, Inc. is a biotechnology company focused on accelerating drug development through its organ-on-a-chip technology. Based in the Republic of Korea, the firm operates at the intersection of biotech R&D and medical technology, serving as a contract research organization (CRO) for its clients.
The company's core business revolves around providing human-relevant preclinical testing services to overcome the limitations of traditional animal models. BioSpero addresses the high failure rate of drugs in human clinical trials—where over 90% of candidates that appear safe in animals ultimately fail—by offering more predictive assessments. The business model is centered on providing services and its proprietary OrganXpert platform to pharmaceutical companies and research institutions, aiming to reduce the time and cost of drug discovery. This is particularly timely, as regulatory bodies like the FDA are actively promoting the use of New Approach Methodologies (NAMs) to reduce reliance on animal testing.
BioSpero's flagship product is the OrganXpert™, a microphysiological system (MPS) that emulates the complex functions of human organs on microfluidic chips. This platform can model various organs, including the liver, kidney, skin, and the blood-brain barrier, as well as cancer models. A key technological differentiator is its pump-free and tubing-free design, which minimizes contamination risks and simplifies operation. The system integrates 3D co-culture capabilities with blood flow simulation to create a microenvironment that closely mimics human physiology, allowing for more accurate predictions of a drug's efficacy and toxicity. The company offers several models, such as the OrganXpert-M Pro, -O, and -T, each tailored for different research needs, from high-throughput screening to compatibility with diverse biological models.
Keywords: organ-on-a-chip, microphysiological systems, preclinical testing, drug development, contract research organization, toxicity testing, 3D cell culture, animal model alternatives, biotechnology, medical technology